BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37260707)

  • 21. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.
    Rao BC; Lou JM; Wang WJ; Li A; Cui GY; Yu ZJ; Ren ZG
    Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):109-115. PubMed ID: 32037278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma.
    Zhu W; Shi P; Liang A; Zhu Y; Fu J; Yuan S; Wu X
    BMC Cancer; 2022 Oct; 22(1):1061. PubMed ID: 36241994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
    Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
    Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
    Lewinska M; Santos-Laso A; Arretxe E; Alonso C; Zhuravleva E; Jimenez-Agüero R; Eizaguirre E; Pareja MJ; Romero-Gómez M; Arrese M; Suppli MP; Knop FK; Oversoe SK; Villadsen GE; Decaens T; Carrilho FJ; de Oliveira CP; Sangro B; Macias RIR; Banales JM; Andersen JB
    EBioMedicine; 2021 Nov; 73():103661. PubMed ID: 34740106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
    Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Jirun P; Zhang G; Kim HK; Ha SA; Zhongtian J; Shishi Q; Zhuqingqing C; Lei G; Yoo J; Kim S; Park YG; Wang J; Yang Y; Xu Z; Huang Z; Lee YK; Song EY; Kim JW
    Dis Markers; 2011; 30(6):307-15. PubMed ID: 21725159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of
    Xu W; Jiang Y; Tao J; Liu Y; Xia Y; Chen C; Jiang X
    J Med Microbiol; 2023 Jun; 72(6):. PubMed ID: 37338093
    [No Abstract]   [Full Text] [Related]  

  • 31. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
    Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.
    Comunale MA; Wang M; Rodemich-Betesh L; Hafner J; Lamontagne A; Klein A; Marrero J; Di Bisceglie AM; Gish R; Block T; Mehta A
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1222-9. PubMed ID: 21467232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A preliminary study of serum marker alpha-enolase in the diagnosis of hepatocellular carcinoma].
    Luo X; Wei YQ; Hai L; Hu YC; Zhao ZJ; Ma WL; Ma LN; Liu XY; Ding XC
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):505-510. PubMed ID: 31357775
    [No Abstract]   [Full Text] [Related]  

  • 35. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
    Chen F; Dai X; Zhou CC; Li KX; Zhang YJ; Lou XY; Zhu YM; Sun YL; Peng BX; Cui W
    Gut; 2022 Jul; 71(7):1315-1325. PubMed ID: 34462336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.
    Piñero F; Vazquez M; Baré P; Rohr C; Mendizabal M; Sciara M; Alonso C; Fay F; Silva M
    Ann Hepatol; 2019; 18(3):480-487. PubMed ID: 31023615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis.
    Zhu J; Huang J; Zhang J; Chen Z; Lin Y; Grigorean G; Li L; Liu S; Singal AG; Parikh ND; Lubman DM
    J Proteome Res; 2020 Aug; 19(8):3452-3466. PubMed ID: 32412768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma.
    Li X; Li B; Li B; Guo T; Sun Z; Li X; Chen L; Chen W; Chen P; Mao Y; Zeng Y
    Pathol Oncol Res; 2018 Jul; 24(3):663-670. PubMed ID: 28828637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma.
    Jiao C; Cui L; Piao J; Qi Y; Yu Z
    J Cancer Res Ther; 2018; 14(6):1239-1244. PubMed ID: 30488837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
    Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
    Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.